[Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002].
The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem; at present, 7 years after available for commercial use.
Yamaguchi
Keizo
K
Department of Microbiology, Toho University School of Medicine.
Ishii
Yoshikazu
Y
Iwata
Morihiro
M
Yoshida
Hiroshi
H
Satoh
Toshio
T
Watanabe
Naoki
N
Uehara
Nobuyuki
N
Murakami
Masami
M
Takahashi
Ayako
A
Yasujima
Minoru
M
Kasai
Takeshi
T
Itoh
Kouichi
K
Shibuya
Yasuhiro
Y
Suwabe
Akira
A
Obata
Ritsuko
R
Kanno
Harushige
H
Kubo
Setsuko
S
Kaku
Mitsuo
M
Kanemitsu
Keiji
K
Maesaki
Shigefumi
S
Hashikita
Giichi
G
Igari
Jun
J
Oguri
Toyoko
T
Aihara
Masanori
M
Kinoshita
Shohiro
S
Okada
Jun
J
Tazawa
Yoko
Y
Taminato
Tomohiko
T
Negayama
Kiyoshi
K
Nakashima
Hideki
H
Takemura
Hiromu
H
Murase
Mitsuharu
M
Miyamoto
Hitoshi
H
Horii
Toshinobu
T
Kusano
Nobuchika
N
Mihara
Eiichirou
E
Baba
Hisashi
H
Ishigo
Shiomi
S
Kambe
Masayuki
M
Itaha
Hideyuki
H
Fujita
Naohisa
N
Komori
Toshiaki
T
Ono
Junko
J
Yoshimura
Hisae
H
Ichiyama
Satoshi
S
Maeda
Shigetaka
S
Hirakata
Yoichi
Y
Matsuda
Junichi
J
Yamanaka
Kiyoharu
K
Murata
Yoko
Y
Saikawa
Tetsunori
T
Hiramatsu
Kazufumi
K
D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology; D015780:Carbapenems / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D007564:Japan; D000077731:Meropenem; D011358:Product Surveillance, Postmarketing; D013845:Thienamycins / Q000494:pharmacology*; D013997:Time Factors
D015780:Carbapenems; D013845:Thienamycins; D000077731:Meropenem